The mechanism of action of the potent antibiotic empedopeptin was not known. Results: Empedopeptin forms calcium-dependent complexes with peptidoglycan precursors, particularly lipid II. Conclusions: Bacterial cell wall synthesis is blocked by sequestration of the bactoprenol carrier. Significance: This mechanism is proposed for a wider class of structurally related antibiotics including empedopeptin, the tripropeptins and plusbacins.
INTRODUCTION
Empedopeptin is an amphoteric, cyclic lipodepsipeptide produced by the Gram-negative soil bacterium Empedobacter haloabium ATCC 31962. Two accompanying publications in 1984 described its isolation, structure determination and antibacterial activity in vitro and in vivo (1, 2) . Empedopeptin showed potent antibacterial activity against a broad range of aerobic and anaerobic Gram-positive bacteria, including the important pathogens Staphylococcus aureus, Streptococcus pneumoniae and Clostridium difficile. Minimal inhibitory concentrations (MIC) in the low µg/ml range for susceptible as well as antibiotic-resistant isolates, substantial therapeutic efficacy in lethal blood-stream infections in mice, good pharmacokinetic parameters and low acute toxicity form a promising profile for the compound (1) , especially in the light of rising vancomycin-resistance among staphylococci and enterococci. Therefore, we revisited empedopeptin and elucidated its molecular mechanism of action.
The overall negatively charged, water-soluble empedopeptin consists of an octapeptide core, cyclized by an ester bond, and a C 14 -myristic acid tail (2) (Fig. 1A) . The macrolactone core comprises altering stretches of D-and Lconfigured amino acids (arginine, proline and serine) as well as the non-proteinogenic amino acids hydroxyaspartic acid and hydroxyproline. Empedopeptin has considerable structural similarity to the lipodepsipeptides of the tripropeptin and plusbacin group (3) (4) (5) (6) (7) . The lower portion of the octapeptide core, which contains the three hydroxy amino acids plus arginine is actually identical in empedopeptin, the tripropeptins (A-E, Z) and plusbacins (A1-B4) (4), whereas moderate variations occur in the amino acid composition of the upper ring segment as well as the fatty acid side chain (Fig. 1B) . The lipid tails occur branched or unbranched and are variable in length, the latter directly influencing antimicrobial activity. Although produced by different organisms, these lipodepsipeptides can basically be regarded as variants of the same structural scaffold.
It has been previously demonstrated that plusbacin A3 interferes with bacterial peptidoglycan biosynthesis (8) , although the specific enzymatic reaction or target structure had remained elusive. While work on this publication was in progress it was reported that tripropeptin C can bind to undecaprenyl-pyrophosphate (C 55 -PP), thereby inhibiting the activity of undecaprenylpyrophosphate phosphatase (UppP) (9) . Here, we show that empedopeptin exerts its antibacterial action by inhibition of peptidoglycan synthesis. However, using a comprehensive set of purified late-stage peptidoglycan synthetic enzymes and the corresponding purified substrates we demonstrate that this class of lipopeptide antibiotics sequesters further peptidoglycan precursors besides C 55 -PP and that the primary target of empedopeptin is lipid II, which is bound in a Ca 2+ -dependent fashion.
EXPERIMENTAL PROCEDURES
Production and purification of empedopeptin. -Production of empedopeptin by E. haloabium ATCC 31962 on a 3 liter scale and extraction of the broth with butanol were performed as described (1) . The crude butanol extract was subjected to reversed-phase (RP) vacuum liquid chromatography, using stepwise gradient elution from H 2 4 OAc) over a period of 15 min and 65:35-90:10 over a 5-min period, followed by isocratic elution at 90:10 for an additional 10 min (Macherey-Nagel Nucleosil 120-5 C 18 , 250 x 4 mm, 5 µm; 0.8 ml/min flow rate; UV monitoring at 210 nm) afforded 6.2 mg of pure empedopeptin.
Antibiotic susceptibility testing. -MICs were determined by standard broth microdilution, according to the CLSI guidelines (10), in polypropylene microtiter plates (Nunc brand) using cation-adjusted Mueller-Hinton broth (Oxoid). Experiments were conducted in the presence and absence of 1.25 mM Ca 2+ , which equates to the concentration of ionized calcium in human serum (11) . Precursor incorporation studies. -To study the effect of empedopeptin on the synthesis of the major bacterial biopolymers, Bacillus subtilis was grown in Belitzky defined minimal medium (12) and the incorporation of tritium-labeled precursors (uridine, thymidine, phenylalanine and N-acetylglucosamine (GlcNAc); 0.02 MBq/ml) into the acid-precipitable cell fraction was measured as described previously (13) . Cultures were incubated with empedopeptin at a concentration of 8 µg/ml and with vancomycin at 0.25 µg/ml, both corresponding to 8 x MIC in this medium. Belitzky medium contains 2 mM Ca 2+ . Determination of the membrane potential. -The membrane potential was determined by a previously described method (14) using the lipophilic cation tetraphenylphosphonium (TPP + ) that diffuses across the bacterial membrane in response to a trans-negative Δψ. 1 µCi/ml of [ 3 H]-TPP + (26 Ci/mmol) was added to a culture of S. aureus SG511 (OD 600 0.7) in half-concentrated Mueller-Hinton broth at 37°C supplemented with 1.25 mM Ca 2+ and cell-bound radioactivity was determined after filtration. For calculation of the membrane potential, cell-associated versus free TPP + concentrations were applied to the Nernst equation. Culture aliquots were treated with empedopeptin (10 µg/ml, corresponding to 10-fold MIC) and the uncoupler carbonyl cyanide mchlorophenylhydrazone (CCCP, 500 µM) as a control.
Quantification of intracellular UDP-N-acetylmuramic acid pentapeptide (UDP-MurNAc-pp). -We followed the protocol of Kohlrausch and
Höltje to analyze the cytoplasmic nucleotide precursor pool (15) . Staphylococcus aureus ATCC 29213 was grown in 20 ml of half-concentrated Mueller-Hinton broth with 1.25 mM Ca 2+ to an OD 600 of 0.6 and incubated with 130 µg/ml of chloramphenicol for 15 min. Chloramphenicol is necessary to prevent, under the impact of the antibiotic under investigation, induction of autolytic processes and de novo synthesis of enzymes hydrolyzing the nucleotide-activated sugars thereby interfering with determination of the soluble precursor (16) . Empedopeptin was added at 40 µg/ml and vancomycin at 5 µg/ml (both 10 x MIC) and incubated for another 45 min. Extraction of UDP-linked peptidoglycan precursors with boiling water and their analysis by HPLC was performed as described previously (17) . Mass spectrometric confirmation of UDPMurNAc-pp was conducted using a MALDI-TOF mass spectrometer (Bruker Biflex, Bruker Daltronics, Bremen, Germany) working in a linear negative mode. An aliquot of the HPLC fraction containing UDP-MurNAc-pp was mixed with 6-aza-2-thiothymine in 50 % (v/v) ethanol/ 20 mM ammonium citrate as matrix material and spotted onto a ground steel MALDI target plate. Mass spectra were recorded in the range of 1000 to 1500 Da and analyzed by Flexanalysis (Bruker Daltronics).
In vitro lipid II synthesis with membrane preparations of Micrococcus luteus.-In vitro lipid II synthesis was performed using membranes of M. luteus as described (18, 19 (20) and phosphomolybdic acid staining (21) . Quantification was carried out by phosphoimaging in a Storm TM imaging system (GE Healthcare). Empedopeptin (molecular weight 1126,2 Da) was added in molar ratios of 0.5-2 with respect to C 55 -P. Synthesis and purification of lipid II on a preparative scale was performed as described (21, 22 ( 2 1 ) .
In vitro transglycosylation was determined by incubating 2 nmol [ 14 C]-lipid II in 100 mM MES, 10 mM MgCl 2 , pH 5.5 in a total volume of 50 µl. The reaction was initiated by the addition of 7.5 µg PBP2-His 6 and incubated for 1.5 h at 30°C (24) . In all in vitro assays empedopeptin was added in molar ratios ranging from 0.5 to 2 with respect to the amount of C 55 -P, lipid I and lipid II, respectively. 1.25 mM Ca 2+ was added as indicated. Synthesized lipid intermediates were extracted from the reaction mixtures with nbutanol/pyridine acetate, pH 4.2 (2:1; vol/vol), analyzed by TLC as described above and quantified by phosphoimaging. In the PBP2 assay reaction mixtures were applied directly onto the thin layer plates without extraction and were developed in solvent B (butanol-acetic a c i d -w a t e r -p y r i d i n e (15:3:12:10, vol/vol/vol/vol)). Experimental details related to assaying MraY, TagO and UppP are provided as supplementary material.
Complex formation of empedopeptin with lipid I / II and C 55 -PP. -Binding of empedopeptin to C 55 -PP, lipid I or lipid II was analyzed by incubating 2 nmol of each purified cell wall precursor with 1 to 8 nmol empedopeptin in 50 mM Tris/HCl, pH 7.5, supplemented with 1.25 mM Ca 2+ for 30 min. Analysis of complex formation between empedopeptin and the respective peptidoglycan precursor was carried out by applying reaction mixtures directly onto TLC plates and developing the plates in solvent B (butanol-acetic acid-water-pyridine (15:3:12:10, vol/vol/vol/vol)). Lipid containing peptidoglycan precursors were detected by phosphomolybdic acid staining.
Antagonization assays. -Antagonization of the antibiotic activity of empedopeptin by potential target molecules was performed by a MIC-type assay setup in microtiter plates. Empedopeptin (8 µg/ml corresponding to 8 x MIC) in MuellerHinton broth with 1.25 mM Ca 2+ was mixed with potential antagonists (UDP-GlcNAc, UDPMurNAc-pp, C 55 -P, farnesyl-PP, C 55 -PP, lipid I, lipid II, lipid III and lipid I variants with shortened stem peptides) in 0.156-to 10-fold molar excess with respect to the antibiotic. B. subtilis 168 (5 x 10 5 cfu/ml) was added and visible bacterial growth was recorded after overnight incubation. The concentration of purified peptidoglycan precursors was quantified on the basis of their phosphate content as described (26) .
Quartz crystal microbalance. -Quartz crystals were prepared and cleaned as described previously (27) . Supported bilayers were completed by transferring a monolayer consisting of 90 mol% POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) / 10 mol% DOPG (1,2-dioleoylsn-glycero-3-phospho-(1'-rac-glycerol)) onto a covalently fixed C 16 H 33 SH-monolayer using the Langmuir-Blodgett technique. Fitting the quartz crystals into the flow chamber was performed under water to guarantee the integrity of the bilayer. Empedopeptin was investigated at 1 µM in the presence and absence of 1.25 mM CaCl 2 . A LiquiLab21 quartz crystal microbalance (ifake.V., Barleben, Germany) was employed, which enables the simultaneous detection of frequency and damping changes in real time. Measurements and calculation of the kinetic binding constants were performed as described (28, 29) .
RESULTS
Antimicrobial activity of empedopeptin. -Empedopeptin exhibited potent antibacterial activity against multi-resistant staphylococci and streptococci including methicillin-resistant S. aureus (MRSA) and penicillin-resistant S. pneumoniae (PRSP) (Tab. 1). The activity against enterococci was moderate in general, but notably included vancomycin-resistant isolates. Escherichia coli was only marginally affected, in accordance with the lack of activity reported earlier for other Gram-negative species (1), which probably reflects insufficient penetration of the rather large (1126.2 Da), net-negatively charged compound through the outer membrane. Minimal inhibitory concentrations of empedopeptin were strongly influenced by the concentration of calcium ions in the culture medium. Addition of 1.25 mM Ca 2+ , equating the Ca 2+ -concentration in human serum (11) , to standard Mueller Hinton broth reduced the MIC values two-to sixteen-fold depending on the test strain. It is important to note in this context that the calcium levels recommended by the Clinical Laboratory Standards Institute for cation adjusted MuellerHinton broth (20-25 mg/l Ca 2+ ) (10) were not sufficient to achieve full empedopeptin activity.
Metabolic pathway targeted by empedopeptin. -To study the impact of the antibiotic on the biosynthetic capacity of intact bacterial cells, we followed the incorporation of radiolabeled metabolic precursors into bacterial macromolecules. Empedopeptin at 8-fold the MIC rapidly and strongly interfered with the incorporation of [ 3 H]-GlcNAc into the cell wall of B. subtilis, whereas DNA and protein biosynthesis remained unaffected (Fig. 2 ). Incorporation of [ 3 H]-uridine into RNA was also diminished after prolonged exposure of the cells to the antibiotic (30 min). This can be explained by the fact that empedopeptin triggered a substantial accumulation of a soluble UDP-activated peptidoglycan precursor (UDP-N-acetyl-muramic acid pentapeptide) in the bacterial cytoplasm as outlined below, thereby depleted the uridine pool for RNA synthesis. Vancomycin, an established and specific inhibitor of peptidoglycan synthesis, induced a comparable effect at 8 x MIC (Fig. 2) . Peptidoglycan synthesis takes place in two different cellular compartments. At first, several cytoplasmic enzymes assemble the soluble, activated UDP-N -acetylmuramic acid pentapeptide (UDP-MurNAc-pp). The sugarpeptide moiety is then transferred to the membrane anchor undecaprenyl phosphate (C 55 -P) to yield a membrane-standing monomer, which is further decorated, flipped across the membrane to the exterior and incorporated into the 3-dimensional peptidoglycan network. In order to distinguish, whether empedopeptin interferes with peptidoglycan synthesis in the cytoplasmic versus the membrane-associated phase, we determined the cytoplasmic levels of UDP-MurNAc-pp. Antibiotics that interfere with the late stages of peptidoglycan synthesis, such as vancomycin, are known to trigger an accumulation of this ultimate soluble peptidoglycan precursor in the cytoplasm. Treatment of S. aureus with empedopeptin (10 x MIC) led to a significant accumulation of UDPMurNAc-pp, similar to vancomycin-treated controls at corresponding multiples of the MIC (Fig. 3 A) .
The results with whole cells indicated peptidoglycan synthesis as the target pathway of empedopeptin. However, as the antibiotic structure contains a lipophilic tail of considerable length, we also investigated, whether the compound might cause additional damage to the cytoplasmic membrane. Disruption of membrane integrity results in a strong decrease of the membrane potential ΔΨ. To determine ΔΨ in the presence of empedopeptin we quantified the intracellular versus extracellular concentration of the tritium-labeled lipophilic cation tetraphenylphosphonium (TPP + ), which diffuses freely across the bacterial membrane in response to a trans-negative ΔΨ. When growing cells of S. aureus were treated with the antibiotic, only a slight drop of membrane potential by 20 mV was observed followed by rapid recovery (Fig. 3B) . In contrast, the addition of the uncoupling ionophor carbonyl cyanide m -chlorophenylhydrazone resulted in a substantial ΔΨ decrease of about 70 mV (Fig. 3B) .
Impact of empedopeptin on in vitro peptidoglycan biosynthesis. -The biosynthesis of the bacterial cell wall requires the coordinated interplay of a number of enzymes and their respective substrates. (For an overview on the reactions involved see Fig. 6 in the discussion section.) After completion of UDP-MurNAc-pp synthesis in the cytoplasm the membrane-bound enzyme MraY couples the sugar-peptide precursor to the lipid carrier C 55 -P yielding lipid I (30) . The transferase MurG subsequently adds GlcNAc to the muramic acid moiety of lipid I yielding lipid II (31) . This central cell wall building block is characteristically modified in different species. In staphylococci, the peptidyltransferases FemXAB catalyze the attachment of a specific pentaglycine interpeptide bridge to the stem peptide (21, 32) , before the precursor is translocated across the cytoplasmic membrane (33) and incorporated into the peptidoglycan network. As our studies with intact bacterial cells had suggested an inhibitory activity of empedopeptin on membrane-associated stages of peptidoglycan synthesis, we next investigated the effect of the antibiotic in various in vitro systems capable of the respective reactions.
Membrane preparations of M. luteus catalyze the membrane-associated synthesis of lipid II by MraY and M u r G in vitro, in the presence of defined amounts of the soluble precursors UDPMurNAc-pp and UDP-GlcNAc as well as the bactoprenol carrier C 55 -P. In the control reaction without antibiotic C 55 -P was completely converted to lipid II by the sequential activity of MraY and MurG, whereas addition of empedopeptin reduced the amount of lipid II (Fig. 4A) . Quantitative analysis using [
14 C]-UDP-GlcNAc to specifically label lipid II revealed a concentration dependent reduction of the lipid II amount. Addition of equimolar concentrations of empedopeptin with respect to C 55 -P resulted in a 50% decrease in extracted lipid II and a two-fold molar excess of antibiotic led to an almost complete absence of lipid II (Fig. 4B) .
Target of empedopeptin and impact of Ca 2+ on target interaction. -To narrow down the molecular target of empedopeptin and to elucidate the role of Ca 2+ in the inhibitory process, individual peptidoglycan biosynthesis reactions were analyzed in vitro using the purified, recombinant proteins MraY, MurG, FemX and PBP2 together with their respective purified substrates in presence and absence of empedopeptin. Testing the MurG catalyzed conversion of lipid I to lipid II as well as the incorporation of the first glycine residue into lipid II by recombinant FemX and the transglycosylation reaction by PBP2, we found all three reactions to be inhibited in a concentrationdependent manner (Fig. 4, C-F) . The addition of Ca 2+ considerably enhanced the effect of empedopeptin and led to a complete inhibition of the reactions at a 2:1 stoichiometry of empedopeptin to lipid precursor. Approximately physiological concentrations of calcium (1 to 1.25 mM) were required for empedopeptin to exert full inhibition, as exemplified for the FemX catalyzed glycine addition (Fig. 4F) .
To It is important to note that empedopeptin inhibited the MurG, FemX and PBP2 reactions at comparable concentrations, which made a specific interference with one of the enzymes highly unlikely and pointed to an interaction with the peptidoglycan precursors instead. The three enzymes discussed so far utilize undecaprenylpyrophosphate containing peptidoglycan precursors that include also a sugar moiety. In contrast, two enzymes that use the structurally simpler C 55 -P as substrate were unaffected by empedopeptin, when applied in the same molar ratio, namely MraY catalyzing the synthesis of lipid I (Fig. S1, supplementary material) and TagO catalyzing the formation of undecaprenol-PPGlcNAc (lipid III), the first membrane bound lipid intermediate of teichoic acid biosynthesis (34, 35) (Fig. S2, supplementary material) . Moreover, dephosphorylation of C 55 -PP by UppP (36) was also not markedly inhibited at a twofold molar excess of empedopeptin over C 55 -PP (Fig. S3,  supplementary material) .
Binding site of empedopeptin at the peptidoglycan precursors. -The interaction of empedopeptin with different undecaprenol-bound peptidoglycan precursors was directly demonstrated by incubating each lipid precursor with the antibiotic in buffer in various molar ratios followed by analysis v i a thin layer chromatography (Fig. 5) . Free lipid I and II were clearly visible at defined positions in the chromatogram, while free empedopeptin was not detectable by the phosphomolybdic acid staining method applied. In complex with empedopeptin, lipid I and II migrated considerably slower and remained close to the application spot. In accordance with the results obtained in the enzyme reaction assays described above, a twofold molar excess of empedopeptin was sufficient for full sequestration of the peptidoglycan precursors lipid I and II in a stable complex that even withstood solvent treatment during separation by thin layer chromatography. In contrast, even a fourfold molar excess of the antibiotic could not trap undecaprenylpyrophosphate in a stable complex under these conditions (Fig. 5) . Notwithstanding, empedopeptin had some influence on the migration behavior of undecaprenylpyrophosphate during thin layer chromatography, because the lipid moved as a more focused band in the presence of the antibiotic (compare Fig. 5C  lane 1 to lane 2 to 4) .
In order to narrow down the region of the lipid precursors that interacts with empedopeptin, we performed antagonization assays with diverse cell wall precursors and truncated variants thereof (Tab. 2). A concentration of empedopeptin corresponding to 8 x MIC was pre-incubated with a 0.156 to 10-fold molar excess of the potentially antagonizing agents before being tested for growth inhibition of B. subtilis in Ca 2+ -supplemented (1.25 mM) culture broth. Lipid II and lipid I showed the strongest antagonizing effect on the antimicrobial activity of empedopeptin, confirming that the antibiotic is effectively trapped in a complex with the purified peptidoglycan precursors. Hence, it is no longer available for interaction with its membranestanding targets, when added to the cells. A lipid I congener with the peptide side-chain shortened by the three C-terminal amino acids was only slightly less effective in antagonization. Also, lipid III and C 55 -PP still retained substantial antagonizing potential, although their affinity for empedopeptin decreased in that order. In contrast, C 55 -P and the nucleotide activated peptidoglycan sugars had no effect in the concentration range tested (Tab. 2).
Interaction of empedopeptin with model membranes. -The target sites of empedopeptin are embedded among the phospholipid head groups of the cytoplasmic membrane. Bearing in mind the structure of empedopeptin with its hydrophobic C 14 myristic acid tail, it is highly likely that the antibiotic establishes close contacts with the membrane that might also promote target binding. To determine the affinity of empedopeptin for phospholipids bilayers per se, we used the quartz crystal microbalance (QCM) biosensor technique. The capacity of the antibiotic to interact with model membranes was investigated on the basis of the mass increase that occurs upon its binding to the lipid bilayer. A mixture of POPC and 10 mol% DOPG served as a model system for the negatively charged bacterial membranes. Kinetic binding constants, such as k ass , k diss , and k D , were calculated from the QCM frequency curves in the presence and absence of the physiological calcium concentration. Empedopeptin demonstrated a high membrane affinity in accordance with its overall hydrophobic nature (Tab. 3). Addition of calcium further increased membrane affinity by approximately 2.5-fold, resulting from a higher association rate and a diminished dissociation rate. The rapid association kinetics and the K D values match those of the lantibiotic gallidermin (37) . Cyclic voltammetry revealed membrane perturbation upon binding, suggesting a tight contact of the antibiotic with the lipid layer (data not shown).
DISCUSSION
The lipodepsipeptide empedopeptin inhibits bacterial growth by blocking peptidoglycan biosynthesis. It forms complexes with undecaprenyl pyrophosphate containing cell wall precursors, thereby interrupting the lipid cycle and depleting the utilizing enzymes of their substrates. Empedopeptin displayed the highest affinity for both lipid I and II. Several distinct assay systems 8 indicated a 2:1 binding stoichiometry of antibiotic to lipid precursors and the complex was remarkably stable even in the presence of the butanol/pyridine acetate used to develop the thin layer plates depicted in figure 5 .
The presence of Ca 2+ ions, in a concentration as they occur in human serum (11) , was required for full inhibitory activity of empedopeptin in our in vitro peptidoglycan synthesis assays. As several of these assay systems contained purified enzymes and substrates, it can be excluded that this stimulating effect is merely due to facilitated interaction of the antibiotic with the bacterial membrane. Rather, our data suggest that calcium markedly promotes the direct interaction of empedopeptin with its target. Empedopeptin is an amphipathic molecule with a hydrophobic region containing the myristoyl side chain and two proline residues opposite to a decidedly hydrophilic, net-negative region that includes the arginine as well as two aspartic acid residues. It is reasonable to conclude that positively charged calcium ions play a crucial role in bridging the antibiotic to the pyrophosphate region of the lipid precursors. Considering the 2:1 stoichiometry of the complex, Ca 2+ ions might also facilitate the formation of empedopeptin dimers by bridging two aspartic acid moieties. In addition, our study with target-free artificial phospholipids layers (Tab. 3) demonstrates that the interaction with negatively charged membranes is also enhanced in the presence of calcium. The strong decrease of the MIC values in media containing physiological calcium concentrations (Tab. 1) indicates that these ionic effects are critical for the antibacterial activity of empedopeptin.
Calcium ions are also involved in the interaction of other antibiotics with peptidoglycan precursors. Recently it was demonstrated that the antibiotic activity of friulimicin B is dependent on the Ca 2+ -mediated complex formation with C 55 -P (38) . Calcium was also shown to promote the interaction of particular lantibiotics carrying the mersacidin-type binding motif with their target lipid II, although the antibiotic activity was only slightly enhanced in these cases (39) .
Our phospholipid binding study demonstrated high affinity of empedopeptin for negatively charged membranes per se. The electric currents detected by cyclic voltammetry on model membranes even pointed to membrane perturbations upon empedopeptin binding. The effects detected in this model membrane system correlated with a slight drop of the membrane potential of bacterial cells after empedopeptin addition. However, the effect on ΔΨ was only temporary and there was no indication for a significant disturbance of membrane integrity. Rather, this effect suggests an intimate interaction of the lipophilic antibiotic with the cytoplasmic membrane in accordance with its membrane standing targets. Along the same line, the continuation of DNA, RNA and protein synthesis in the presence of empedopeptin precludes a gross depolarization of the cytoplasmic membrane. These biosynthetic processes are highly energy consuming and require constant ATP replenishment by oxidative phosphorylation. Also, the fact that UDP-MurNAc-pp accumulated in the cytoplasm indicates a functional membrane barrier, because the precursor was retained inside the cells.
In antagonization assays very low amounts of externally added lipid I or lipid II were sufficient to fully complex free empedopeptin and to prevent its interaction with bacterial cells (Tab. 2). Among the different peptidoglycan precursors tested, lipid II and lipid I were equally well bound by the antibiotic indicating that the second sugar GlcNAc is not crucial for the interaction. The C-terminal region of the stem peptide containing the L-lysyl-D-alanyl-D-alanine moiety does also not significantly contribute to binding, as obvious from the comparison of lipid I with lipid I(dipeptide). This result highlights that the target site of empedopeptin differs from that of the glycopeptide antibiotics (40) and is in accordance with the activity of empedopeptin against vancomycin-resistant bacterial isolates. However, if the cell wall precursor lacks the whole stem peptide and the lactyl moiety of MurNAc, as it occurs in lipid III, its potential for complex formation is fourfold lower than that of lipid I or lipid II. Undecaprenyl pyrophosphate as such is also recognized by empedopeptin, but the absence of the GlcNAc moiety further reduced the affinity by a factor of two. It is also noteworthy that in a similar antagonization study with tripropeptin C 20 -PP showed stronger antagonizing potential than C 15 -PP (9) , suggesting that the undecaprenyl chain does also take part in the interaction. In summary, the interaction of empedopeptin with lipid II appears to involve the pyrophosphate group, the first sugar, and the first one or two amino acids of the stem peptide as well as the proximal part of the undecaprenyl chain (Fig. 6) .
Due to its comparably large size empedopeptin will probably not enter the bacterial cell. Whether it can flip across the membrane to interact with lipid I that resides within the inner phospholipid leaflet is questionable and remains to be studied. Therefore, the surface exposed lipid II appears as the likely physiological target of empedopeptin. Since lipid II is bound with high affinity, its sequestration at low antibiotic concentrations and concomitant inhibition of peptidoglycan biosynthesis is probably the primary killing event.
As shown for a variety of other antibacterial agents among them lipopeptides, lantibiotics and defensins (25, 41) , lipid II binding is sufficient to prevent the synthesis of novel peptidoglycan followed by bacterial cell lysis and death. Bacterial cells exposed to a lipid II binder do not merely suffer from inhibition of the transglycosylation step in peptidoglycan synthesis, but from interruption of the lipid cycle and general depletion of the undecaprenyl pool. Depletion of free bactoprenol inhibits several reactions in peptidoglycan synthesis and also the membraneassociated stages of teichoic acid and capsule biosynthesis, which also rely on C 55 -P as carrier.
However, empedopeptin differs from several other lipid II binders described to date (e.g. mersacidin and plectasin) (18, 25) ) by its affinity for additional bactoprenol-containing precursors that appear outside the cell. C 55 -PP can be sequestered, as probably can be the lipid III structural motif within extracellular teichoic acid precursors (e.g. within C 55 -PP-GlcNAc-N-acetylmannosamine-(glycerolphosphate) 2 -(ribitolphosphate) in S. aureus) (42) . Among these structures empedopeptin has the highest affinity for lipid II, which we consider its primary and main interaction site. However, if bacterial cells are exposed to sufficiently high empedopeptin concentrations, the antibiotic will probably recognize the other structures as well, thereby trapping the bactoprenol carrier at more than one stage in parallel. As interaction with multiple targets is beneficial in the light of reduced resistance development (43, 44) this characteristic is an advantage of empedopeptin.
While this work was in progress a report on the mechanism of action of tripropeptin C was published, proposing C 55 -PP as the primary target and its dephosphorylation as the target reaction (9) . The authors based their conclusion on biosynthesis reactions with bacterial membrane fractions and a MIC-type antagonization assay with externally added C 55 -PP. Similar to our results they found that the activity of tripropeptin C was antagonized by a comparably high molar excess of C 55 -PP. However, neither the purified lipids I, II, or III nor purified peptidoglycan biosynthetic enzymes were employed in this study. As a consequence, the assay systems applied did not allow for measuring the affinity of tripropeptin C for the full spectrum of peptidoglycan precursors or to investigate individual enzyme reactions separately in the absence of other interfering precursors and enzymes. On the basis of the clear results obtained in our defined systems and in the light of the strong structural similarity between empedopeptin, the tripropeptins and the plusbacins (Fig. 1) we propose that complex formation with lipid II as primary target and with C 55 -PP and the lipid III moiety as secondary targets represents the mechanism of antibacterial action for this entire class of compounds.
ABBREVIATIONS:
The abbreviations used are: CCCP, carbonyl cyanide m-chlorophenylhydrazone; C 55 -P, undecaprenylphosphate; C 55 -PP, undecaprenyl-pyrophosphate; DOPG, 1,2-dioleoyl-sn-glycero-3-phospho-(1'-racglycerol; EMP, empedopeptin; GlcNAc, N-acetyl-glucosamine; lipid I, undecaprenyl-pyrophosphate-Nacetyl-muramic acid(pentapeptide); lipid II, undecaprenyl-pyrophosphate-N-acetyl-muramic acid (pentapeptide)-N-acetyl-glucosamine); lipid II-Gly 1 , undecaprenyl-pyrophosphate-N-acetyl-muramic acid (pentapeptide-glycine)-N-acetyl-glucosamine; lipid III, undecaprenyl-PP-GlcNAc; MIC, minimal inhibitory concentration; MRSA, methicillin-resistant Staphylococcus aureus; OD, optical density; POPC, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; PRSP, penicillin-resistant Streptococcus pneumoniae; QCM, quartz crystal microbalance; RP, reversed-phase; TLC, thin layer chromatography; TPP + , tetraphenylphosphonium; UDP-MurNAc-pp, UDP-N-acetyl-muramic acid pentapeptide; VRE, vancomycin-resistant Enterococcus. Starting from UDP-GlcNAc the ultimate soluble precursor UDP-MurNAc is synthesized in the cytoplasm by the sequential action of MurA to MurF enzymes. Lipid I is formed in the first membrane-associated step at the inner face of the membrane by MraY, which transfers the soluble sugar-peptide moiety to the lipid carrier C 55 -P. The transferase MurG subsequently links a GlcNAc moiety to the muramoyl portion of lipid I, yielding lipid II. In S. aureus lipid II is further decorated by the addition of five glycine residues, catalyzed by FemXAB enzymes. Finally, lipid II is translocated across the membrane and the peptidoglycan-monomer is incorporated into the growing peptidoglycan network by transglycosylation and transpeptidation. Once the lipid II monomer appears at the outside of the cytoplasmic membrane, empedopeptin binds to it in a Ca 2+ -dependent manner at a region involving the pyrophosphate group, the first sugar and the proximal parts of the stem peptide and the undecaprenyl chain. Dimerization of empedopeptin may occur in the course of this process. C 55 -PP is also bound at the outer leaflet of the cytoplasmic membrane, but with lower affinity than lipid II. Size, shape and positioning of all components are schematic and not based on structural data. PBPs, penicillin binding proteins. 
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